






NanoteC is one of the longest running series of international nanoscale carbon conferences in 
Europe (since 1998). It brings together scientists working with nanoscale carbon materials: 
nanotubes, graphene, diamond- and fullerene-related nanostructures. While each of these materials 
attracts its own dedicated community of researchers, NanoteC draws on common themes and 
allows researchers to share insight into this unique element at the nanoscale. 
Elemental carbon shows remarkable variety in properties via simple covalent bonding, however 
other systems (for example containing nitrogen or metals) are becoming important and provide 
alternative components with unique mechanical and electronic properties. Nanotechnology 
requires an understanding of these materials on an atomic level and this will be the central theme. 
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Carbon nanomaterials are promising as drug nanocarriers suitable for medical treatments, due to their 
large surface area and chemical stability that allows efficient loading of drugs via both covalent and 
non-covalent interactions [1-3]. A combination of increased tumor vascular permeability and 
insufficient lymphatic drainage, resulting in what is termed as enhanced permeability and retention 
(EPR) effect, enables these nanomaterials to transport chemotherapeutic agents preferentially to 
tumor sites as compared to healthy tissues, thereby reducing toxic side effects [4]. Furthermore, these 
systems could be used for formulation of hydrophobic molecules which lack of suitable 
physicochemical characteristics required for development of stable pharmaceutical dosage form. 
Camptothecin (CPT) is a potent anticancer agent with topoisomerase I inhibiting activity whose 
practical use in viable cancer therapeutic systems is greatly hampered due to its high hydrophobicity 
and therefore low solubility in biological media [5]. The need to formulate water-soluble salts of CPT 
led to chemical modifications of the molecule with loss of anti-tumor activity [6,7]. Thus, developing 
new drug delivery nanocarriers for CPT able to transport and deliver the drug inside the cancer cells 
would be of high interest. 
In this work, the potential in the field of CPT drug delivery for different nanocarriers such as carbon 
nanotubes (CNT), graphene oxide (GO), reduced graphene oxide (RGO) and carbon nanodiamonds 
(ND) were systematically compared under the same experimental conditions. In vitro studies were 
performed on human epithelial colorectal adenocarcinoma (Caco-2) cells and human breast 
adenocarcinoma (MCF-7) cells. Carbon nanomaterials able to establish strong – interactions with 
CPT provided the highest anticancer activity [8]. 
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